Question Bank › From candidate to default

From candidate to default

From candidate to default: the company has just been placed inside buyers' own purchasing systems

Calls Tested
498
Answered YES
12
Hit Rate
2.4%
rare by design

SI-BONE, Inc. (SIBN) — this company's answers

NO on the Q3 2022 call 2022-11-07 C+
The model's full reasoning — Q3 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权”的买家采购、报销、配方、规格、采购、网络、目录或计划系统中的选择,从而使得公司未来业务的相当一部分可以在没有每次订单的单独销售事件的情况下到达,并且管理层是否传达了这种准入状态是新的,以至于它所带来的大部分交易量仍在前方,尚未反映在报告的结果中。 在记录中,管理层讨论了CMS最终规则,该规则提高了SI关节融合手术的设施报销率。这可以被视为一种报销途径的准入,但需要判断这是否是“新的”且“大部分交易量仍在前方”。管理层说:“今天,我们80%的微创SI关节手术是在门诊或手术中心进行的。随着这些手术继续转移到ASC,2023年更高的报销可能成为需求的顺风,并允许我们维持我们的定价和服务地点。”这暗示了报销率的提高可能带来需求,但并未明确说公司已被列入某个批准清单或成为默认选择。此外,管理层提到“我们继续成功与美国各大医院合作,将产品列入批准清单”,但这是针对iFuse-Bedrock Granite的,且过程是“通常需要几天到几周”的,这表明这是新产品的常规上市过程,而非公司整体地位的转变。 管理层还提到“我们继续看到网站流量高、患者参与度高、外科医生转诊和我们的Find A Doctor定位器指标”,但这些都是营销指标,不是采购系统准入。 关于报销,管理层说:“基于最终规则,2023年微创SI关节融合手术在ASC和医院门诊的设施报销将分别增加约26%至17,109美元和33%至21,898美元。”这确实是一个报销途径的改善,但这是针对整个行业的,并非公司独有的准入。而且,管理层没有说这是公司最近才获得的,而是说“今天,80%的微创SI关节手术是在门诊或手术中心进行的”,这表明这种报销途径已经存在,只是报销金额增加。此外,管理层没有说大部分未来业务将来自这个报销途径,而是说“可能成为需求的顺风”,这暗示了它可能带来增量,但并非根本性的转变。 关于“被列入批准清单”,管理层提到“我们继续成功与美国各大医院合作,将产品列入批准清单”,但这是针对Granite的,且是新产品上市的正常过程,并非公司整体地位的转变。而且,管理层说“这个过程通常需要几天到几周”,这表明这是常规操作,并非新近获得的准入。 因此,管理层没有描述公司从“候选”转变为“默认”的明确现象。报销率的提高是行业性的,并非公司独有的准入。批准清单是针对新产品的,且是常规过程。没有迹象表明公司已进入一个“无需每次销售”的途径,且大部分未来业务尚未反映。 因此,答案应为NO。

← Back to the full SIBN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: the company has moved from candidate toward default inside the routine pathway through which purchases get made. Example forms, all treated equally: being named to an approved or preferred supplier list, procurement schedule, purchasing program, or payer network; being written into specifications, standards, reference designs, configurations, protocols, or bundled defaults; being added to a formulary, reimbursement catalog, coding/payment pathway, formulary-like listing, or provider directory; being qualified onto a customer's, agency's, platform's, or program's roster; or comparable status that inserts the company into the system through which transactions routinely flow. The essential point is the EXCHANGE OF FRICTION STATUS: buying no longer has to be re-argued each time, because the company is now inside the pathway. For YES, management must also convey, directly or plainly in substance, that the status is recent and the flow through it is only beginning — so the results just reported capture little of what this access will bring. One such gateway, or several together, both qualify. Answer NO if the only access described is ordinary selling relationships, routine reseller/distribution agreements, or standard customer wins where each order still must be individually persuaded. NO if the relevant status has existed for years and is simply the company's steady way of going to market, with nothing new about the access. NO if the status is only pending, applied for, hoped for, or contingent on approvals not yet obtained. NO if management merely asserts that the product is "mission-critical," "a standard," or "the default choice" without describing a concrete buyer-side system the company has been placed into. NO if the business flowing through that status is already mature and substantially reflected in current results. NO if the access status or its significance appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
INGN Inogen, Inc. Q1 2023 2023-05-05 F
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.

More from the question bank

Paying a named price today to serve businessEarnings outrunning the activityAnalysts converge on an emerging driverWorking harder than they are being paid forNumbers reset the ceilingDeliberately different by designAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.